Literature DB >> 34883342

Fluvastatin enhances IL-33-mediated mast cell IL-6 and TNF production.

Marcela T Taruselli1, Elizabeth Motunrayo Kolawole2, Amina Abdul Qayum1, Tamara T Haque1, Heather L Caslin2, Daniel Abebayehu3, Sydney A Kee2, Jordan M Dailey1, Kaitlyn G Jackson1, Jason R Burchett1, Andrew J Spence2, Neha Pondicherry2, Brian O Barnstein2, Gregorio Gomez4, David B Straus2, John J Ryan5.   

Abstract

Statins are HMG-CoA reductase inhibitors prescribed for lowering cholesterol. They can also inhibit inflammatory responses by suppressing isoprenylation of small G proteins. Consistent with this, we previously found that fluvastatin suppresses IgE-mediated mast cell function. However, some studies have found that statins induced pro-inflammatory cytokines in macrophages and NK cells. In contrast to IgE signaling, we show that fluvastatin augments IL-33-induced TNF and IL-6 production by mast cells. This effect required the key mast cell growth factor, stem cell factor (SCF). Treatment of IL-33-activated mast cells with mevalonic acid or isoprenoids reduced fluvastatin effects, suggesting fluvastatin acts at least partly by reducing isoprenoid production. Fluvastatin also enhanced IL-33-induced NF-κB transcriptional activity and promoted neutrophilic peritonitis in vivo, a response requiring mast cell activation. Other statins tested did not enhance IL-33 responsiveness. Therefore, this work supports observations of unexpected pro-inflammatory effects of some statins and suggests mechanisms by which this may occur. Because statins are candidates for repurposing in inflammatory disorders, our work emphasizes the importance of understanding the pleiotropic and possible unexpected effects of these drugs.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Allergy; IL-33; Inflammation; Mast cell; Statin

Mesh:

Substances:

Year:  2021        PMID: 34883342      PMCID: PMC8782378          DOI: 10.1016/j.cellimm.2021.104457

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  67 in total

1.  Statins enhance the anti-inflammatory effects of inhaled corticosteroids in asthmatic patients through increased induction of indoleamine 2, 3-dioxygenase.

Authors:  Kittipong Maneechotesuwan; Wuttichai Ekjiratrakul; Kanda Kasetsinsombat; Adisak Wongkajornsilp; Peter J Barnes
Journal:  J Allergy Clin Immunol       Date:  2010-10       Impact factor: 10.793

2.  Statin use and survival from lung cancer: a population-based cohort study.

Authors:  Chris R Cardwell; Úna Mc Menamin; Carmel M Hughes; Liam J Murray
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-05       Impact factor: 4.254

Review 3.  IL-33/ST2 axis in inflammation and immunopathology.

Authors:  Marija Milovanovic; Vladislav Volarevic; Gordana Radosavljevic; Ivan Jovanovic; Nada Pejnovic; Nebojsa Arsenijevic; Miodrag L Lukic
Journal:  Immunol Res       Date:  2012-04       Impact factor: 2.829

4.  Atorvastatin in combination with inhaled beclometasone modulates inflammatory sputum mediators in smokers with asthma.

Authors:  Neil C Thomson; Catherine E Charron; Rekha Chaudhuri; Mark Spears; Kazuhiro Ito; Charles McSharry
Journal:  Pulm Pharmacol Ther       Date:  2015-01-14       Impact factor: 3.410

5.  Fluvastatin Suppresses Mast Cell and Basophil IgE Responses: Genotype-Dependent Effects.

Authors:  Elizabeth Motunrayo Kolawole; Jamie Josephine Avila McLeod; Victor Ndaw; Daniel Abebayehu; Brian O Barnstein; Travis Faber; Andrew J Spence; Marcela Taruselli; Anuya Paranjape; Tamara T Haque; Amina A Qayum; Qasim A Kazmi; Dayanjan S Wijesinghe; Jamie L Sturgill; Charles E Chalfant; David B Straus; Carole A Oskeritzian; John J Ryan
Journal:  J Immunol       Date:  2016-01-15       Impact factor: 5.422

Review 6.  Update on statin-mediated anti-inflammatory activities in atherosclerosis.

Authors:  Fabrizio Montecucco; François Mach
Journal:  Semin Immunopathol       Date:  2009-05-05       Impact factor: 9.623

Review 7.  Targeting GSK3 and Associated Signaling Pathways Involved in Cancer.

Authors:  Przemysław Duda; Shaw M Akula; Stephen L Abrams; Linda S Steelman; Alberto M Martelli; Lucio Cocco; Stefano Ratti; Saverio Candido; Massimo Libra; Giuseppe Montalto; Melchiorre Cervello; Agnieszka Gizak; Dariusz Rakus; James A McCubrey
Journal:  Cells       Date:  2020-04-30       Impact factor: 6.600

8.  Statin use and asthma control in patients with severe asthma.

Authors:  Amir A Zeki; Justin Oldham; Machelle Wilson; Olga Fortenko; Vishal Goyal; Michael Last; Andrew Last; Ayan Patel; Jerold A Last; Nicholas J Kenyon
Journal:  BMJ Open       Date:  2013-08-13       Impact factor: 2.692

9.  Release of both preformed and newly synthesized tumor necrosis factor alpha (TNF-alpha)/cachectin by mouse mast cells stimulated via the Fc epsilon RI. A mechanism for the sustained action of mast cell-derived TNF-alpha during IgE-dependent biological responses.

Authors:  J R Gordon; S J Galli
Journal:  J Exp Med       Date:  1991-07-01       Impact factor: 14.307

10.  Attenuation of airway inflammation by simvastatin and the implications for asthma treatment: is the jury still out?

Authors:  Jing-Nan Liu; Dong-Hyeon Suh; Eun-Mi Yang; Seung-Ihm Lee; Hae-Sim Park; Yoo Seob Shin
Journal:  Exp Mol Med       Date:  2014-09-12       Impact factor: 8.718

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.